Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II, Multicenter, Randomized, Single-Masked, Sham Injection-Controlled Study of Safety, Tolerability, and Evidence of Activity of FCFD4514S Intravitreal Injections Administered Monthly or Every Other Month to Patients With Geographic Atrophy

NCT01229215 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT01229215
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01229215 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II, Multicenter, Randomized, Single-Masked, Sham Injection-Controlled Study of Safety, Tolerability, and Evidence of Activity of FCFD4514S Intravitreal Injections Administered Monthly or Every Other Month to Patients With Geographic Atrophy
Lead sponsor
Genentech, Inc.
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2011
Completion date
April 30, 2013
Enrollment
143 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

geographic atrophy